Clinical trials: Helicobacter Pylori Infection
Helicobacter Pylori Infection
Comparing the Efficacy of Reverse Hybrid Therapy and Bismuth Quadruple Therapy
Reverse hybrid therapy achieves a higher eradication rate than bismuth quadruple therapy remained unanswered.
- Trial name
- NCT02547038
- Testing
- pantoprazole+bismuth+tetra+metro, (panto+amox+clar+metr)+(panto+amox)
- Where
- Taiwan
- Volunteers
- 352 people
- Sponsor
- Kaohsiung Veterans General Hospital.
Helicobacter Pylori Infection
High Dose Dual Therapy vs Clarithromycin Triple Therapy for Treatment Naive H Pylori Infection in an Urban Population
A phase 4 prospective, randomized, open-label clinical trial evaluating the efficacy of high dose dual therapy vs standard triple therapy in a diverse, urban New York City population.
- Trial name
- NCT05342532
- Testing
- Amoxicillin, Omeprazole, Clarithromycin
- Where
- United States
- Volunteers
- 112 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Functional Dyspepsia, Gastritis
The Prevalence and the Pathophysiological Role of Non-Helicobacter Pylori Helicobacter Spp. in Well-defined Gastric Diseases and (Pre-) Malignancies
The goal of this clinical trial is to discover the prevalence of NHPH bacteria (Non-Helicobacter pylori Helicobacter species) in patients with one of the following conditions: 1.
- Conditions
- Functional Dyspepsia, Gastritis, Gastritis Chronic, Gastric Cancer (GC)
- Trial name
- HELIS (NCT07770126)
- Where
- 3 sites in Belgium
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Universiteit Antwerpen
Helicobacter Pylori Infection
Molecular Detection of Antibiotic Resistance and H Pylori Eradication
H pylori eradication failure with recommended triple therapy is mainly related to antibiotic resistance. However,IN VITRO culture of H pylori is uneasy and is not performed in routine practice.
- Trial name
- HELICOSTIC (NCT01168063)
- Testing
- Molecular detection of antibiotic resistance, standard triple therapy (PPI, amoxicillin, clarithromycin, metronidazole)
- Where
- France
- Volunteers
- 1,386 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Helicobacter Pylori Infection, Compliance, Patient
Comparison of Bismuth Containing Quadruple Therapy and Based Tailored Therapy for H. Pylori Infection
As the antibiotic resistance increases, the eradication rate of triple therapy is decreasing. Recent guideline recommend the use of bismuth-containing quadruple therapy in areas where clarithromycin resistance is greater than…
- Conditions
- Helicobacter Pylori Infection, Compliance, Patient, Drug Resistance, Antibiotics
- Trial name
- NCT03361267
- Testing
- Helicobacter pylori PCR test, CLO test
- Where
- South Korea
- Volunteers
- 300 people
- Sponsor
- Inha University Hospital
Infection, Achlorhydria
Clinical Experiment of Helicobacter Pylori Transmission
The study proposes to test whether chronic infection with Helicobacter pylori protects individuals from symptomatic infection with enteropathogenic E. coli.
- Trial name
- NCT00550368
- Testing
- Biological intervention: Enteropathogenic E. coli
- Where
- United States
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- Stanford University
Helicobacter Pylori Infection
Efficacy of Acetylcysteine-containing Triple Therapy in the First Line of Helicobacter Pylori Infection
Helicobacter pylori infection has been shown to be associated with the development of gastric cancer and peptic ulcer diseases. Eradication of H. pylori infection could reduce the occurence or recurrence of these diseases.
- Trial name
- NCT02249546
- Testing
- N-acetylcysteine + PPI-amoxicillin-clarithromycin, PPI-amoxicillin-clarithromycin
- Where
- 2 sites in Taiwan
- Volunteers
- 654 people
- Sponsor
- National Taiwan University Hospital
H Pylori Gastritis, H Pylori Infection
Efficacy of Carminal in Helicobacter Pylori Gastritis
Eighty patients will be included and randomized in two groups, one group (40 patients) will be administered 30 ml of the supplement Carminal, once a day, plus therapy for HP gastitis and the control group (40 patients) will be…
- Conditions
- H Pylori Gastritis, H Pylori Infection, H Pylori Eradication, Gastritis Associated With Helicobacter Pylori
- Trial name
- NCT07179237
- Testing
- Carminal Oral solution
- Where
- 2 sites in Serbia
- Volunteers
- 80 people
- Sponsor
- Catalysis SL
HELICOBACTER PYLORI INFECTIONS, Metabolic Syndrome
H. Pylori Infection and Metabolic Syndrome: A Retrospective Cross-Sectional Study
This retrospective cross-sectional study evaluates the association between Helicobacter pylori infection and metabolic syndrome using health examination data from 5,218 adults at Nanjing First Hospital.
- Trial name
- NCT07651202
- Testing
- No intervention. This is an observational study.
- Where
- China
- Volunteers
- 5,218 people
- Sponsor
- Nanjing First Hospital, Nanjing Medical University
Helicobacter Infections
Endofaster Test for Helicobacter Pylori Detection in Patients on Proton Pump Inhibitor Therapy
H. pylori infection is the most important causative agent of gastritis, and subsequent atrophic gastritis. The endoscopic diagnosis of H. pylori infection relies on urease tests such as the Clo test.
- Trial name
- NCT02126722
- Testing
- Gastroscopy, EndoFaster test, Clo test
- Where
- United Kingdom
- Volunteers
- 150 people
- Sponsor
- Niso Biomed S.R.L.
Helicobacter Pylori Infections, Atrophic Gastritis
Multicentric Randomized Study of H. Pylori Eradication and Pepsinogen Testing for Prevention of Gastric Cancer Mortality
Currently no ideal preventive modalities are available for reducing gastric-cancer caused mortality in organized population-based application.
- Conditions
- Helicobacter Pylori Infections, Atrophic Gastritis, Gastric Cancer
- Trial name
- GISTAR (NCT02047994)
- Testing
- Triple therapy
- Where
- Latvia
- Volunteers
- 30,000 people, healthy volunteers welcome
- Sponsor
- International Agency for Research on Cancer
Duodenal Ulcer, Helicobacter Pylori Infection
Relation of Metabolic Rate of Omeprazole and Eradication of Helicobacter Pylori Infection
The aims of this study are (1) to evaluate the prevalence rate of PM of CYP2C19 in our country; (2) to evaluate the efficacy of dual therapy with different dose of omeprazole and amoxicillin; (3) to judge the relationship of…
- Trial name
- NCT00854451
- Testing
- omeprazole plus amoxicillin
- Where
- Taiwan
- Volunteers
- 128 people
- Sponsor
- National Taiwan University Hospital
Helicobacter Infections
Levofloxacin Versus Clarithromycin Triple Therapy in First-Line Treatment for Helicobacter Pylori Eradication
Clarithromycin-based triple therapy containing a proton-pump inhibitor (PPI) twice daily, amoxicillin 1g twice daily, and clarithromycin 500 mg twice daily for 7 days is one of the standard firs-line therapy for Helicobacter…
- Trial name
- NCT00816140
- Testing
- Cravit based triple therapy, Klaricid based triple therapy
- Where
- Taiwan
- Volunteers
- 432 people, healthy volunteers welcome
- Sponsor
- National Taiwan University Hospital
Erosive Esophagitis, Heartburn
A Study to Evaluate Vonoprazan Concentrations in Breast Milk of Healthy Lactating Women Receiving Vonoprazan 20 mg Once Daily or Vonoprazan 20 mg Twice Daily
The primary objective is to determine the pharmacokinetics (PK) of vonoprazan in breast milk of healthy lactating women who have received vonoprazan administered once daily or vonoprazan 20 mg administered twice daily for 4…
- Conditions
- Erosive Esophagitis, Heartburn, Symptomatic Nonerosive Gasroesophageal Reflux Disease, Helicobacter Pylori Infection
- Trial name
- NCT06391177
- Testing
- Vonoprazan
- Where
- United States
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Phathom Pharmaceuticals, Inc.
Helicobacter Pylori Infection
Impact of Periodontal Treatment on Gastric Helicobacter Pylori Eradication
The efficacy of conventional systemic antibiotic therapy for eradication of gastric H. pylori has been seriously challenged by antibiotic resistance.
- Trial name
- NCT03654781
- Testing
- Triple therapy, professional periodontal treatment
- Volunteers
- 98 people
- Sponsor
- Ondokuz Mayıs University
Helicobacter Pylori Infection
Efficacies of Hybrid and High-dose Dual Therapies for the First-line Anti-H Pylori Treatment
Both hybrid and high-dose dual therapies developed by the scholars from Taiwan can achieve a high eradication rate for clarithromycin-resistant strains, and have a great potential to replace bismuth quadruple therapy in the…
- Trial name
- NCT05152004
- Testing
- Pariet, Amolin, Klaricid
- Where
- Taiwan
- Volunteers
- 240 people
- Sponsor
- Chang Gung Memorial Hospital
Acute Coronary Syndrome, Helicobacter Pylori Infection
The Effect of Dual Eradication Therapy vs PPI on Gastrointestinal Bleeding in ACS Patients
Patients with acute coronary syndrome (ACS) after Percutaneous Coronary Intervention (PCI) require routine treatment with dual antiplatelet (DAPT) treatment, but with the high risk of bleeding, gastrointestinal bleeding is the…
- Trial name
- NCT04728516
- Testing
- Vonoprazan-based dual eradication therapy for two weeks, amoxicillin, Pantoprazole
- Where
- 42 sites in China
- Volunteers
- 2,600 people
- Sponsor
- Qilu Hospital of Shandong University
Residents of Palau Aged 18 Years or Older
Prevalence of Helicobacter Pylori Infection
1. To investigate the prevalence of Helicobacter pylori infection among adults in Palau using stool antigen testing. 2. To analyze the correlation between H.
- Trial name
- NCT07840833
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Fu Jen Catholic University Hospital
Helicobacter Pylori Infection, Obesity, Morbid
THE EFFECT OF HELICOBACTER PYLORI ERADICATION THERAPY TO GASTRIC WALL THICKNESS BEFORE THE LAPAROSCOPIC SLEEVE GASTRECTOMY
Laparoscopic sleeve gastrectomy is one of the most popular bariatric surgery in the world. The most important complication about this surgery that the leakage from the stapler line because of the inconvenient stapler choice..The…
- Trial name
- NCT03757650
- Testing
- Bismuth Subsalicylate
- Where
- Turkey (Türkiye)
- Volunteers
- 3 people
- Sponsor
- Fatih Sultan Mehmet Training and Research Hospital
Helicobacter Pylori Infection
Quadruple Versus Sequential Therapy for Helicobacter Pylori Eradication
Helicobacter pylori (HP), a bacterium present in many people's stomachs, is one of the major causes of ulcers and cancers. Up to 20% of patients infected with H. pylori may develop peptic ulcers.
- Trial name
- NCT01760824
- Testing
- Sequential therapy, Quadruple therapy
- Where
- Hong Kong
- Volunteers
- 391 people
- Sponsor
- The University of Hong Kong